RCA
CHRS icon

Riverview Capital Advisers’s Coherus Oncology CHRS Stock Holding History

Riverview Capital Advisers’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,946
Closed -$21.2K – 93
2025
Q3 		$21.2K Buy
+12,946
New +$14.4K 0.01% 98

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Riverview Capital Advisers's CHRS Position: Q4 2025 in Review

Riverview Capital Advisers sold out of Coherus Oncology (CHRS) in Q4 2025, closing a stake of 12,946 shares — an estimated $21.2K sold.

Riverview Capital Advisers first reported a position in CHRS in Q3 2025 and held it in 1 quarter. The position peaked at $21.2K in Q3 2025. 128 funds tracked by Wall St. Rank hold CHRS as of Q4 2025.

  • Riverview Capital Advisers reported no remaining Coherus Oncology position as of Q4 2025 after selling out during the quarter.
  • Riverview Capital Advisers sold 12,946 Coherus Oncology shares in Q4 2025, an estimated $21.2K.
  • Riverview Capital Advisers first reported a position in Coherus Oncology in Q3 2025 and held it in 1 quarter.
  • Riverview Capital Advisers's Coherus Oncology position peaked at $21.2K in Q3 2025.
  • 128 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2025.

Based on Riverview Capital Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.